Newly launched injectable drug which has created a lot of buzz in both medical and lifestyle sector. Mounjaro – the brand named for tirzepatide molecule, has quickly become the hype in the town for its promising and obvious clinical impacts on both glycemic control and weight loss. What found as a treatment for type 2 diabetes is now unfolding its potential in in the world of obesity management.

In March 2022, FDA approved the Mounjaro- once weekly injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. What makes it clinically unique is its dual-action mechanism. It mimics not only one, but two hormones that is GLP-1 and GIP. This two helps to regulate blood sugar, appetite, and metabolism. This dual targeting sets it apart from drugs like Semaglutide (Ozempic, Wegovy), which only targets on GLP-1.

How it Works
In simple terms, tirzepatide slows down the movement of food through the stomach, curbs the hunger signals in brain and enhance the insulin sensitivity — so in short tirzepatide is a shot of powerful trio. SURPASS Clinical program have shown that people using Mounjaro has resulted in improvement in the blood glucose parameters i.e. FPG, PPG, HbA1c. Alongside there is impressive weight loss which is around 15-20% and this is comparable to surgical outcomes. As revealed in SURMOUNT study, significant transition in weight has not only caught the attention of physicians but also the celebrities, influencers and the wellness community.

Why Mounjaro is creating the massive hype?
Mounjaro stands out for its clinical support in managing both obesity and type 2 diabetes, particularly when lifestyle changes like proper diet and regular exercise is not working enough. So, for many struggling people this has offers hope, and a head start towards better health. But it is also important to understand that “Mounjaro is a supportive medication, not a substitute for healthy lifestyle”. It should be used alongside a healthy routine. Proper diet, regular physical activity, and routine follow-ups still having important place during Mounjaro treatment.

Just like all the medicines, Mounjaro also has the side effects which include nausea, vomiting, constipation and rarely, it can cause serious health issues like pancreatitis. High costed Mounjaro has not been covered by all insurance plans. And while it’s approved for diabetes, its use for weight loss under the brand name – Zepbound in the U.S., is still being navigated in many countries.

Mounjaro may be the latest breakthrough, but health isn’t just found in a syringe. It’s found in sustainable habits, smart choices, and the commitment to long-term well-being.

-Dr Prashanth Arun, Senior Physician & Diabetologist, MV Hospital for Diabetes.